D. Gandara

1.1k total citations
26 papers, 837 citations indexed

About

D. Gandara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, D. Gandara has authored 26 papers receiving a total of 837 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in D. Gandara's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). D. Gandara is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). D. Gandara collaborates with scholars based in United States, Australia and France. D. Gandara's co-authors include Sari H. Enschede, Charles M. Rudin, Geoffrey I. Shapiro, Andrew Krivoshik, Philip M. Hemken, Christine L. Hann, Divis Khaira, Moacyr Oliveira, Leena Gandhi and Yi‐Lin Chiu and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and European Journal of Cancer.

In The Last Decade

D. Gandara

26 papers receiving 814 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Gandara United States 11 478 377 203 97 85 26 837
Elgilda Musi United States 13 450 0.9× 304 0.8× 148 0.7× 71 0.7× 117 1.4× 25 852
Manish Monga United States 13 582 1.2× 478 1.3× 158 0.8× 45 0.5× 67 0.8× 37 1.0k
Philip Bonomi United States 15 592 1.2× 593 1.6× 403 2.0× 140 1.4× 112 1.3× 37 1.2k
Carla Kurkjian United States 17 481 1.0× 302 0.8× 157 0.8× 58 0.6× 60 0.7× 41 830
Raymond Wadlow United States 14 484 1.0× 485 1.3× 179 0.9× 138 1.4× 51 0.6× 36 944
Teeru Bihani United States 14 530 1.1× 388 1.0× 353 1.7× 73 0.8× 82 1.0× 27 1.1k
Kristy J. Gotink Netherlands 7 609 1.3× 294 0.8× 252 1.2× 108 1.1× 42 0.5× 8 975
Arthur Clements Australia 16 559 1.2× 704 1.9× 128 0.6× 87 0.9× 84 1.0× 21 996
Michelle L. Kraus United States 7 466 1.0× 447 1.2× 124 0.6× 38 0.4× 101 1.2× 9 1.1k

Countries citing papers authored by D. Gandara

Since Specialization
Citations

This map shows the geographic impact of D. Gandara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Gandara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Gandara more than expected).

Fields of papers citing papers by D. Gandara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Gandara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Gandara. The network helps show where D. Gandara may publish in the future.

Co-authorship network of co-authors of D. Gandara

This figure shows the co-authorship network connecting the top 25 collaborators of D. Gandara. A scholar is included among the top collaborators of D. Gandara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Gandara. D. Gandara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mack, Philip C., Mary W. Redman, Khaled Tolba, et al.. (2021). MA08.10 LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis. Journal of Thoracic Oncology. 16(3). S163–S164. 2 indexed citations
2.
Gandara, D.. (2019). GR02.04 Immunotherapy: Hyperprogression and Treatment Beyond Progression. Journal of Thoracic Oncology. 14(10). S85–S85. 1 indexed citations
3.
Claret, Laurent, Jin Y. Jin, Charles Ferté, et al.. (2018). A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics. Clinical Cancer Research. 24(14). 3292–3298. 53 indexed citations
4.
Ruhaak, L. Renee, Carol Stroble, Jianliang Dai, et al.. (2016). Serum Glycans as Risk Markers for Non–Small Cell Lung Cancer. Cancer Prevention Research. 9(4). 317–323. 21 indexed citations
5.
Raez, Luis E., Edgardo S. Santos, Christian Rolfo, et al.. (2016). Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America. Clinical Lung Cancer. 18(1). e71–e79. 26 indexed citations
6.
Ruhaak, L. Renee, Sandra L. Taylor, Suzanne Miyamoto, et al.. (2013). Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Analytical and Bioanalytical Chemistry. 405(14). 4953–4958. 32 indexed citations
7.
Lwin, Zarnie, Jonathan W. Riess, & D. Gandara. (2013). The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.. PubMed. 5 Suppl 5. S556–64. 24 indexed citations
8.
Gandhi, Leena, D. Ross Camidge, Moacyr Oliveira, et al.. (2011). Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. Journal of Clinical Oncology. 29(7). 909–916. 462 indexed citations
9.
Quinn, David I., Ana M. Aparicio, Denice Tsao‐Wei, et al.. (2009). 7163 Phase II study of eribulin (Halichondrin B analogue, E7389) in patients with advanced urothelial cancer (AUC) – California Cancer Consortium led NCI/CTEP-sponsored trial. European Journal of Cancer Supplements. 7(2). 442–442. 2 indexed citations
10.
Fehrenbacher, L., et al.. (2008). Chemotherapy for Brain Metastases in Small-Cell Lung Cancer. Clinical Lung Cancer. 9(1). 35–38. 25 indexed citations
11.
Natale, Ronald B., Primo N. Lara, Kari Chansky, et al.. (2008). S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). Journal of Clinical Oncology. 26(15_suppl). 7512–7512. 27 indexed citations
12.
Synold, Timothy W., Chris H. Takimoto, James H. Doroshow, et al.. (2007). Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study. Clinical Cancer Research. 13(12). 3660–3666. 38 indexed citations
13.
Shibata, Stephen, Warren Chow, Paul Frankel, et al.. (2006). A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. Cancer Chemotherapy and Pharmacology. 59(4). 549–557. 3 indexed citations
14.
Turrisi, Andrew T., John Crowley, Kathy S. Albain, Laurie E. Gaspar, & D. Gandara. (2005). Southwest Oncology Group: Two Decades of Experience in Non-Small Cell Lung Cancer. Seminars in Oncology. 32(2 Suppl 3). 119–121. 3 indexed citations
15.
Mortenson, Melinda M., Michael G. Schlieman, Subbulakshmi Virudachalam, et al.. (2005). Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer. 49(2). 163–170. 45 indexed citations
16.
17.
18.
Mortenson, Melinda M., M.G. Schlieman, S. Virudachalam, et al.. (2004). Effects of the 26S proteasome inhibitor, bortezomib, on BCL-2 in small cell lung cancer: Implications for SWOG-0327. Journal of Clinical Oncology. 22(14_suppl). 9560–9560. 2 indexed citations
19.
George, C., et al.. (1992). Consolidation hemibody radiotherapy following induction combination chemotherapy in high-tumor-burden multiple myeloma.. Journal of Clinical Oncology. 10(11). 1769–1774. 4 indexed citations
20.
Kohler, Malcolm, et al.. (1987). A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuridine alone.. PubMed. 175–7. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elgilda Musi Breakdown of academic impact, for papers by Manish Monga Breakdown of academic impact, for papers by Philip Bonomi Breakdown of academic impact, for papers by Carla Kurkjian Breakdown of academic impact, for papers by Raymond Wadlow Breakdown of academic impact, for papers by Teeru Bihani Breakdown of academic impact, for papers by Kristy J. Gotink Breakdown of academic impact, for papers by Arthur Clements Breakdown of academic impact, for papers by Michelle L. Kraus
Rankless by CCL
2026